受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（Monte Rosa）股价重挫

路透中文07-31 23:06

BUZZ-受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（<a href="https://laohu8.com/S/GLUE">Monte Rosa</a>）股价重挫

7月31日 - ** 蒙特罗萨治疗公司（GLUE.O）股价下跌31.5%，至四个月低点15.54美元

** 诺和诺德 NOVOb.CO 表示，其试验性药物ziltivekimab在晚期临床试验中，与安慰剂相比未能降低 (link) 发生重大心血管事件的风险

** 蒙特罗萨公司正在开发用于治疗动脉粥样硬化性心血管疾病的MRT-8102，这与诺和诺德试验针对的疾病相同

** 诺和诺德测试的是抗IL-6单克隆抗体ziltivekimab，而MRT-8102是一种NEK7降解剂，作用于NLRP3/炎症小体通路的上游

** 韦德布什（Wedbush）分析师罗伯特·德里斯科尔（Robert Driscoll）表示，诺和诺德试验的失败“与GLUE公司的NEK7降解剂项目MRT-8102具有重要关联”

** 德里斯科尔表示，由于临床降风险进程可能推迟，他将“从我们的估值中剔除MRT-8102的估值贡献”

** “我们预计投资者将下调或剔除MRT-8102在心血管领域所带来的风险调整后价值”——古根海姆分析师

** 诺和诺德（NVO.N）在美上市股价下跌9%

** 截至上一交易日收盘，GLUE今年以来累计下跌0.2%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655776367?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-31 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655776367","market":"us","top_or_hot":-1,"title":"受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（Monte Rosa）股价重挫","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（<a href=\"https://laohu8.com/S/GLUE\">Monte Rosa</a>）股价重挫</title></head><body><p><span>7月31日</span><span> - </span>** 蒙特罗萨治疗公司（<span>GLUE.O</span>）股价下跌31.5%，至四个月低点15.54美元</p><p>** <a href=\"https://laohu8.com/S/NVO\">诺和诺德</a> <span>NOVOb.CO</span> 表示，其试验性药物ziltivekimab在晚期临床试验中，与安慰剂相比未能降低 (<span>link</span>) 发生重大心血管事件的风险</p><p>** 蒙特罗萨公司正在开发用于治疗动脉粥样硬化性心血管疾病的MRT-8102，这与诺和诺德试验针对的疾病相同</p><p>** 诺和诺德测试的是抗IL-6单克隆抗体ziltivekimab，而MRT-8102是一种NEK7降解剂，作用于NLRP3/炎症小体通路的上游</p><p>** 韦德布什（Wedbush）分析师罗伯特·德里斯科尔（Robert Driscoll）表示，诺和诺德试验的失败“与GLUE公司的NEK7降解剂项目MRT-8102具有重要关联”</p><p>** 德里斯科尔表示，由于临床降风险进程可能推迟，他将“从我们的估值中剔除MRT-8102的估值贡献”</p><p>** “我们预计投资者将下调或剔除MRT-8102在心血管领域所带来的风险调整后价值”——古根海姆分析师</p><p>** 诺和诺德（<span>NVO.N</span>）在美上市股价下跌9%</p><p>** 截至上一交易日收盘，GLUE今年以来累计下跌0.2%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（Monte Rosa）股价重挫</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（Monte Rosa）股价重挫\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-07-31 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（<a href=\"https://laohu8.com/S/GLUE\">Monte Rosa</a>）股价重挫</title></head><body><p><span>7月31日</span><span> - </span>** 蒙特罗萨治疗公司（<span>GLUE.O</span>）股价下跌31.5%，至四个月低点15.54美元</p><p>** <a href=\"https://laohu8.com/S/NVO\">诺和诺德</a> <span>NOVOb.CO</span> 表示，其试验性药物ziltivekimab在晚期临床试验中，与安慰剂相比未能降低 (<span>link</span>) 发生重大心血管事件的风险</p><p>** 蒙特罗萨公司正在开发用于治疗动脉粥样硬化性心血管疾病的MRT-8102，这与诺和诺德试验针对的疾病相同</p><p>** 诺和诺德测试的是抗IL-6单克隆抗体ziltivekimab，而MRT-8102是一种NEK7降解剂，作用于NLRP3/炎症小体通路的上游</p><p>** 韦德布什（Wedbush）分析师罗伯特·德里斯科尔（Robert Driscoll）表示，诺和诺德试验的失败“与GLUE公司的NEK7降解剂项目MRT-8102具有重要关联”</p><p>** 德里斯科尔表示，由于临床降风险进程可能推迟，他将“从我们的估值中剔除MRT-8102的估值贡献”</p><p>** “我们预计投资者将下调或剔除MRT-8102在心血管领域所带来的风险调整后价值”——古根海姆分析师</p><p>** 诺和诺德（<span>NVO.N</span>）在美上市股价下跌9%</p><p>** 截至上一交易日收盘，GLUE今年以来累计下跌0.2%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLUE","symbol_name":"Monte Rosa Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4T43X1UN:1","article_id":"2655776367","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655776367","pubTimestamp":1785510382,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（Monte Rosa）股价重挫7月31日-** 蒙特罗萨治疗公司（GLUE.O）股价下跌31.5%，至四个月低点15.54美元** 诺和诺德NOVOb.CO表示，其试验性药物ziltivekimab在晚期临床试验中，与安慰剂相比未能降低 (link) 发生重大心血管事件的风险** 蒙特罗萨公司正在开发用于治疗动脉粥样硬化性心血管疾病","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GLUE":"Monte Rosa Therapeutics","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Monte Rosa shares tumble on news of Novo's cardiovascular clinical trial failure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":0.9},"content_text":"BUZZ-受诺沃（Novo）心血管临床试验失败消息影响，蒙特罗萨（<a href=\"https://laohu8.com/S/GLUE\">Monte Rosa</a>）股价重挫7月31日 - ** 蒙特罗萨治疗公司（GLUE.O）股价下跌31.5%，至四个月低点15.54美元** 诺和诺德 NOVOb.CO 表示，其试验性药物ziltivekimab在晚期临床试验中，与安慰剂相比未能降低 (link) 发生重大心血管事件的风险** 蒙特罗萨公司正在开发用于治疗动脉粥样硬化性心血管疾病的MRT-8102，这与诺和诺德试验针对的疾病相同** 诺和诺德测试的是抗IL-6单克隆抗体ziltivekimab，而MRT-8102是一种NEK7降解剂，作用于NLRP3/炎症小体通路的上游** 韦德布什（Wedbush）分析师罗伯特·德里斯科尔（Robert Driscoll）表示，诺和诺德试验的失败“与GLUE公司的NEK7降解剂项目MRT-8102具有重要关联”** 德里斯科尔表示，由于临床降风险进程可能推迟，他将“从我们的估值中剔除MRT-8102的估值贡献”** “我们预计投资者将下调或剔除MRT-8102在心血管领域所带来的风险调整后价值”——古根海姆分析师** 诺和诺德（NVO.N）在美上市股价下跌9%** 截至上一交易日收盘，GLUE今年以来累计下跌0.2%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655776367","isCrawlerRequest":true}